All News

Follow the fashion: the biotech financing model has changed. But will today’s start-ups be tomorrow’s fashion victims?

Fifteen member states had no system for allowing third party nationals into the EU to carry out scientific research when the deadline for applying the directive passed last week.

Despite the Nobel-induced champagne now flowing in Berlin, Jülich, Paris and Cardiff, the fact remains that Europe has a fundamental problem in the quality of its science.

The European Commission wants to remove the stigma of bankruptcy and give entrepreneurs a second chance.

Biotech and pharma companies have overtaken the technology sector in the European Commission’s annual scoreboard of R&D investment for the first time.

With the French Senate ratifying the London Agreement on patent translation, technology companies can look to a much cheaper future.

Economic impact must be embedded into research policy, says Philip Esler, Chief Executive of the UK’s Arts and Humanities and Research Council.